Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

Share Price is delayed by 15 minutes
Get Live Data
250.00    0.00 (0.00%)
Bid:
245.00
Ask:
255.00
Spread: 10.00 (4.082%)
Market Cap: £227.11m
CNC Live PriceLast checked at - London Stock Exchange

Intraday Concurrent Technologies Share Chart

Post-Close Trading Update

4 Jan 2023 07:00

RNS Number : 5749L
Concurrent Technologies PLC
04 January 2023
 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a Regulatory Information Service, this information is considered to be in the public domain.

 

4 January 2023

Concurrent Technologies Plc

(the 'Company')

 

Post-Close Trading Update

 

Concurrent Technologies Plc (AIM: CNC), a world-leading specialist in the design and manufacture of high-end embedded computer systems and boards for critical applications, is pleased to announce an update on trading for the year ending 31 December 2022 ("FY22").

 

Based on its unaudited management accounts for FY22, the Company expects to report revenues circa 10% ahead of market expectations* and profit before tax at least in line with market expectations**.

 

This was achieved despite the global supply chain shortages which extended lead times throughout the year, delaying manufacture, shipping and revenues. The Company invested significant cash into holding increased inventory to react quickly once parts became available, as happened at the end of FY22. To best manage this recent surge in activity the Company implemented a double shift throughout Q4, resulting in record revenues in November and December 2022. 

 

Cash was depleted throughout the year as a result of the Company's declared strategy of investing in R&D, systems, and growth of its home markets in the US and UK. The additional investment in components holdings to mitigate supply shortages, resulted in a cash low point at the end of FY22, at a value of circa £4M.

 

With the increased shipping of product in November and December 2022, the Company anticipates strong cash generation at the start of FY23, with further episodes of cash generation as components become more available. Whilst overall supply chains are seeing a degree of recovery, the Company is in many cases dependent on some very specific components, and hence FY23 forecasts remain prudently cautious.

 

The Company intends to continue its strategy to invest in growth during FY23, and this includes efforts to make acquisitions that align with a strategy of owning more of the technology building blocks in embedded systems, in addition to single board computers. 

 

FY22 has seen excellent strategic progress. The Company now sells systems products and has received its first purchase orders accordingly. It has also qualified a manufacturing partner in the USA and is therefore capable of selling domestic product in America. In addition, the Company's accelerated R&D efforts are resulting in increased demand for evaluation boards which is the route to being designed into latter production phases that typically last several years.

 

Following a record order intake in FY21 of £25M, the Company is proud to announce order intake for FY22 in excess of £31M, an increase of over 25%. The FY22 closing backlog was also very strong, in excess of £26M. These figures indicate that, as supply chains ease, the Company has potential for significant revenue growth. A further cause for optimism is that the Company expects to run double shifts throughout Q1 FY23, maintaining its increased capacity.

 

The Board previously confirmed a policy of paying dividends from profit generated during the year. Accordingly, the Board does not currently propose to pay a dividend in respect of FY22, with cash instead being used to fund further investment across the business, including in component holdings to mitigate the impact of any potential further restrictions. However, the Board is still committed to the capital discipline of paying a dividend when future profits allow.

 

Chief Executive Officer Miles Adcock said "Whilst the prolonged components shortages have frustratingly slowed down revenue generation, it is clear that our strategy is yielding growth potential. The fact that we have our highest ever backlog, following a record order intake, gives us real optimism for short to mid-term performance growth as supply chains improve. In addition, our longer-term strategies are exciting our customers and colleagues, so it is all to play for."

*Consensus revenue expectations for 2022 are £16m

**Consensus profit before tax expectations for 2022 are £0.1m

 

Enquiries:

Concurrent Technologies Plc

Miles Adcock, CEO +44 (0)1206 752626

Kim Garrod, CFO

 

SEC Newgate (Financial PR)

Bob Huxford +44 (0)20 3757 6880

Isabelle Smurfit +44 (0)20 3757 6880

Harry Handyside concurrent@secnewgate.co.uk

 

Cenkos Securities Plc (NOMAD)

Neil McDonald +44 (0)131 220 9771

Peter Lynch +44 (0)131 220 9772

 

About Concurrent Technologies Plc

Concurrent Technologies Plc develops and manufactures high-end embedded computer products for use in a wide range of high-performance, long-life cycle applications within the telecommunications, defence, security, telemetry, scientific and aerospace markets, including applications within extremely harsh environments. The processor products feature Intel® processors, including the latest generation embedded Intel® Core™ processors, Intel® Xeon® and Intel Atom™ processors. The products are designed to be compliant with industry specifications and support many of today's leading embedded Operating Systems. The products are sold world-wide.

For more information on Concurrent Technologies Plc and its products please visit www.gocct.com.

All trademarks, registered trademarks and trade names used in this announcement are the property of their respective owners.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUOAWROWUARAR
Date   Source Headline
14th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
13th Apr 20267:01 amRNSBoard change
13th Apr 20267:00 amRNSFinal results for the year ended 31 December 2025
31st Mar 20265:24 pmRNSBlock Admission Application
30th Mar 20267:00 amRNSNotice of Results and Investor Presentation
10th Mar 20267:00 amRNSLaunch of Next-Generation Computing Products
25th Feb 20267:00 amRNSHolding(s) in Company
16th Feb 20267:00 amRNSAppointment of Nominated Adviser and Broker
27th Jan 20267:00 amRNSNew Managing Director of Products Appointed
26th Jan 20267:00 amRNSNew Product Announcement
20th Jan 20267:00 amRNSTrading Update
23rd Dec 20257:00 amRNSUpdate on Expanded HQ and Manufacturing Facility
23rd Dec 20257:00 amRNSUpdate on Expanded HQ and Manufacturing Facility
12th Dec 20254:43 pmRNSExercise of Options and TVR
9th Dec 202512:46 pmRNSExercise of Options, Director Dealing and TVR
5th Dec 202512:15 pmRNSExercise of Share Options and Total Voting Rights
27th Nov 20254:46 pmRNSExercise of Options, Director Dealing and TVR
1st Oct 20257:00 amRNSIssue of Share Options and PDMR Dealing
19th Sep 20255:36 pmRNSDirector Share Dealing
19th Sep 20257:00 amRNS$5.25m US Defence Contract Secured
8th Sep 20257:00 amRNSInterim Results
4th Sep 20257:00 amRNSRecord UK defence contract secured for £4m
20th Aug 20257:00 amRNSNew Product Launch
13th Aug 20254:20 pmRNSInvestor Meet Company Presentation Update
12th Aug 20257:00 amRNSLaunch of Compact Computer System
29th Jul 20257:00 amRNSNotice of Results and Investor Presentation
16th Jul 20255:25 pmRNSHolding(s) in Company
15th Jul 20257:00 amRNSH1 FY25 Trading Update
8th Jul 20252:13 pmRNSExercise of Options, New Ordinary Shares and TVR
1st Jul 20255:51 pmRNSHolding(s) in Company
25th Jun 20257:00 amRNSHolding(s) in Company
18th Jun 20252:19 pmRNSExercise of Options, New Ordinary Shares and TVR
13th Jun 20257:00 amRNSResults of Annual General Meeting
23rd May 20251:07 pmRNSExercise of Options, New Ordinary Shares and TVR
16th May 202510:53 amRNSPosting of Annual Report and Notice of AGM
15th May 20251:28 pmRNSHolding(s) in Company
8th May 20257:00 amRNSExercise of Options, New Ordinary Shares and TVR
28th Apr 20257:00 amRNSExercise of Options
24th Apr 20251:25 pmRNSExercise of Options, Director Dealing and TVR
23rd Apr 20254:01 pmRNSHolding(s) in Company
14th Apr 20257:00 amRNSFinal Results for the year ended 31 December 2024
7th Apr 20257:00 amRNSNotice of Results and Investor Presentation
31st Mar 20257:00 amRNSLease agreed for new HQ & manufacturing facility
17th Mar 202510:46 amRNSHolding(s) in Company
3rd Mar 20257:00 amRNSNew Product Announcement
28th Feb 20257:00 amRNSDirector Share Dealing
13th Feb 20257:00 amRNSCommencement of Trading on OTCQX in the U.S.
27th Jan 20257:00 amRNSMajor VME Product Order from Long-Term Customer
17th Jan 20259:22 amRNSHolding(s) in Company
16th Jan 20257:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.